A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

Abroad (travel likely)RecruitingPHASE2

Conditions

Epidermolysis Bullosa Simplex · Genodermatosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

CHU de Nice, Nice, France, France
Contact: Study coordinator (Christine CHIAVERINI) · chiaverini.c@chu-nice.fr · 0492034702
Contact: Study coordinator (Thomas Hubiche) · hubiche.t@chu-nice.fr · 0492034702
APHP Necker-Enfants-Malades, Paris, France, France
Contact: Study coordinator (Christine Bodemer)
APHP Hôpital Saint-Louis, Paris, France, France
Contact: Study coordinator (Emmanuelle Bourrat)
chu de Toulouse, Toulouse, France
Contact: Study coordinator (Juliette MAZEREEUW -HAUTIER)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

Epidermolysis Bullosa Simplex · Ichthyosis · Genodermatosis

Abroad (travel likely)RecruitingPHASE2

Nice, France · Paris, France

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

Epidermolysis Bullosa Simplex

Abroad (travel likely)RecruitingPHASE2

Palo Alto, United States · Chicago, United States